SEZ6L2 and non-small cell lung carcinoma: Patients diagnosed with non-small cell lung cancer (NSCLC) who have tumors showing elevated SEZ6L2 expression levels tend to experience reduced survival times specific to the tumor, in contrast to individuals without SEZ6L2 expression (35).